Nisa Investment Advisors
CRSP icon

Nisa Investment Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Nisa Investment Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$153K Buy
2,809
+50
+2% +$2.63K ﹤0.01% 1350
2026
Q1 		$131K Buy
2,759
+234
+9% +$12.3K ﹤0.01% 1337
2025
Q4 		$132K Hold
2,525
– – ﹤0.01% 1347
2025
Q3 		$164K Buy
2,525
+313
+14% +$18K ﹤0.01% 1297
2025
Q2 		$108K Buy
+2,212
New +$85.6K ﹤0.01% 1370

Other funds holding CRSP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Swiss National Bank
Swiss National Bank Zurich, Switzerland $191B AUM 45.21% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Nisa Investment Advisors's CRSP Position: Q2 2026 in Review

Nisa Investment Advisors increased its CRISPR Therapeutics (CRSP) stake by 1.8% in Q2 2026, buying an estimated $2.63K and bringing the position to 2,809 shares worth $153K. The position accounts for ﹤0.01% of the portfolio, ranked #1350.

Nisa Investment Advisors first reported a position in CRSP in Q2 2025 and has held it in 5 quarters since. The position peaked at $164K in Q3 2025. 280 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Nisa Investment Advisors held 2,809 shares of CRISPR Therapeutics worth $153K as of Q2 2026.
  • Nisa Investment Advisors bought 50 CRISPR Therapeutics shares in Q2 2026, an estimated $2.63K.
  • CRISPR Therapeutics made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q2 2026, its #1350 holding.
  • Nisa Investment Advisors first reported a position in CRISPR Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Nisa Investment Advisors's CRISPR Therapeutics position peaked at $164K in Q3 2025.
  • 280 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Nisa Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.